Alto Neuroscience (ANRO) Corporate presentation summary

Mission and strategic approach

• Aims to redefine psychiatry by developing personalized, neurobiology-driven medicines for mental health conditions, focusing on faster and more effective patient outcomes.

• Utilizes a precision medicine strategy, leveraging pharmacodynamic biomarkers to identify responsive patient populations and reduce development risk.

• Biomarker platform segments heterogeneous clinical populations to improve treatment outcomes and drive patient selection for trials.

Portfolio and clinical pipeline

• Over 900 patients dosed across studies, with more than 25 million patient impact opportunity projected.

• Multiple late-stage data readouts expected in the next three years, with a cash runway through 2029.

• Pipeline includes ALTO-207 (TRD), ALTO-300 (MDD), ALTO-100 (bipolar depression), ALTO-101 (schizophrenia/CIAS), and other candidates, all leveraging biomarker-driven approaches.

ALTO-207 for treatment-resistant depression (TRD)

• Combines a D3/D2 agonist (pramipexole) with a 5-HT3 antagonist (ondansetron) to enhance antidepressant effects and reduce dose-limiting side effects.

• Demonstrated robust antidepressant efficacy and improved tolerability, enabling higher and faster dosing compared to pramipexole alone.

• Phase 2a and meta-analyses show large effect sizes, especially in anhedonia, with a favorable safety profile.

• Phase 2b (potentially pivotal) trial to launch in 1H 2026, topline results expected 2H 2027, with Phase 3 planned for early 2027.

• Strong IP protection and commercial strategies expected to deter generic substitution.